INT118292

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2004
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 27
Total Number 27
Disease Relevance 13.62
Pain Relevance 1.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (EGFR) cell morphogenesis (EGFR) Golgi apparatus (EGFR)
endoplasmic reticulum (EGFR) intracellular (EGFR) enzyme binding (EGFR)
Anatomy Link Frequency
apoptotic cell 4
head 3
colon 2
brain 2
neck 1
EGFR (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 7 95.76 Very High Very High Very High
antagonist 50 91.28 High High
Central nervous system 24 90.08 High High
qutenza 1 86.52 High High
cytokine 10 81.84 Quite High
cINOD 259 79.12 Quite High
aspirin 18 60.80 Quite High
imagery 14 58.64 Quite High
tolerance 8 55.20 Quite High
Inflammation 38 52.32 Quite High
Disease Link Frequency Relevance Heat
Cancer 743 100.00 Very High Very High Very High
Breast Cancer 153 98.98 Very High Very High Very High
Metastasis 79 98.60 Very High Very High Very High
Diarrhoea 42 98.52 Very High Very High Very High
Exanthema 46 97.96 Very High Very High Very High
Colon Cancer 275 97.92 Very High Very High Very High
Skin Infection 3 97.92 Very High Very High Very High
Apoptosis 482 97.72 Very High Very High Very High
Pancreatic Cancer 140 97.36 Very High Very High Very High
Death 111 97.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recent data have shown that it correlates with a decrease in EGFR phosphorylation, decreased invasion, lower nodal involvement, reduced subsequent metastasis, and longer disease-free and overall survival in stage II/III colorectal carcinoma patients who have received curative surgery[26].
Negative_regulation (decrease) of Phosphorylation (phosphorylation) of EGFR associated with colon cancer, disease and metastasis
1) Confidence 0.59 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 1.02 Pain Relevance 0
Histologically, the characteristic thinning of the stratum corneum and folliculitis induced by other EGFR inhibitors was not observed, whereas at the molecular level, nimotuzumab did not suppress EGFR phosphorylation, receptor signaling, or keratinocyte proliferation (Ki-67),56 echoing findings in a head and neck cancer trial.67 Nimotuzumab’s benign side-effect profile is not limited to the epidermis though, as it also includes the absence of severe hypomagnesemia and a lack of grade 3 or 4 gastrointestinal side effects, commonly seen in this class of agents.68,69
Neg (not) Negative_regulation (suppress) of Phosphorylation (phosphorylation) of EGFR in head associated with hypomagnesemia, skin infection and head & neck cancer
2) Confidence 0.58 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2990321 Disease Relevance 0.59 Pain Relevance 0
RESULTS: Lidocaine (> or =400 microM) significantly suppressed EGF-stimulated autophosphorylation of the purified EGFR.
Negative_regulation (suppressed) of Phosphorylation (autophosphorylation) of EGFR
3) Confidence 0.58 Published 2004 Journal Anesthesiology Section Body Doc Link 15114219 Disease Relevance 0 Pain Relevance 0
Small-molecule EGFR TK inhibitors (TKIs) are competetive inhibitors and bind reversibly to the intracellular catalytic domain of EGFR tyrosine kinase and, thus, inhibit EGFR autophosphorylation and downstream signaling.
Negative_regulation (inhibit) of Phosphorylation (autophosphorylation) of EGFR
4) Confidence 0.57 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.34 Pain Relevance 0
Significant inhibition of phosphorylation of the EGFR was observed with gefitinib (50 ?
Negative_regulation (inhibition) of Phosphorylation (phosphorylation) of EGFR
5) Confidence 0.50 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2828989 Disease Relevance 0.14 Pain Relevance 0
Erlotinib inhibited tumour cell proliferation (Ki-67), and phosphorylation of EGFR and HER2.
Negative_regulation (inhibited) of Phosphorylation (phosphorylation) of EGFR associated with cancer
6) Confidence 0.49 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 1.33 Pain Relevance 0
EGFR phosphorylation was significantly decreased in a dose-dependent manner for all eight mutants, with a minimum response at .002 ?
Negative_regulation (decreased) of Phosphorylation (phosphorylation) of EGFR
7) Confidence 0.43 Published 2010 Journal World J Surg Oncol Section Body Doc Link PMC2970593 Disease Relevance 0.13 Pain Relevance 0
We report, for the first time, that sulindac metabolites block both basal and EGF induced phosphorylation of EGFR and downregulate total EGFR protein expression.
Negative_regulation (block) of Phosphorylation (phosphorylation) of EGFR
8) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.30 Pain Relevance 0.36
We now report, for the first time, that sulindac metabolites inhibit EGFR phosphorylation and downregulate the expression of total EGFR protein in human colon cancer cells.
Negative_regulation (inhibit) of Phosphorylation (phosphorylation) of EGFR in colon associated with colon cancer
9) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.66 Pain Relevance 0
In summary, we have described for the first time that sulindac metabolites downregulate EGFR and prevent EGFR phosphorylation by EGF.
Negative_regulation (prevent) of Phosphorylation (phosphorylation) of EGFR
10) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.21 Pain Relevance 0.15
Sulindac metabolites block EGF-induced phosphorylation of EGFR and ERK1/2, downregulate total EGFR protein, and induce apoptotic cell death
Negative_regulation (block) of Phosphorylation (phosphorylation) of EGFR in apoptotic cell associated with apoptosis and death
11) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.45 Pain Relevance 0.03
Both sulindac sulfide and sulindac sulfone downregulate EGFR expression and phosphorylation at comparable doses to those that inhibit ERK1/2 phosphorylation and induce apoptotic cell death (Figures 5 and 6).
Negative_regulation (downregulate) of Phosphorylation (phosphorylation) of EGFR in apoptotic cell associated with apoptosis and death
12) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.74 Pain Relevance 0
Pretreatment with sulindac metabolites for 24 h blocked EGF-induced phosphorylation of both EGFR and ERK1/2 and decreased total EGFR protein expression.
Negative_regulation (blocked) of Phosphorylation (phosphorylation) of EGFR
13) Confidence 0.42 Published 2005 Journal J Carcinog Section Abstract Doc Link PMC1208922 Disease Relevance 0.71 Pain Relevance 0.23
Sulindac metabolites downregulate basal EGFR phosphorylation and expression
Negative_regulation (downregulate) of Phosphorylation (phosphorylation) of EGFR
14) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.34 Pain Relevance 0
Sulindac sulfone treatment resulted in a modest but significant decrease in EGFR phosphorylation as early as 1 h after treatment, and this effect increased and persisted through 24 h (Figure 6A and 6B).
Negative_regulation (decrease) of Phosphorylation (phosphorylation) of EGFR
15) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.15 Pain Relevance 0
Lidocaine (> or = 400 microM) significantly suppressed both the proliferation of HCECs promoted by EGF and EGF-stimulated autophosphorylation of EGFR.
Negative_regulation (suppressed) of Phosphorylation (autophosphorylation) of EGFR
16) Confidence 0.42 Published 2004 Journal Anesthesiology Section Body Doc Link 15114219 Disease Relevance 0 Pain Relevance 0
M sulindac sulfone markedly decreased the ability of EGF to induce phosphorylation of EGFR; total EGFR expression levels and ERK1/2 phosphorylation were also downregulated (Figure 4), albeit to a lesser extent than with sulindac sulfide.
Negative_regulation (downregulated) of Phosphorylation (phosphorylation) of EGFR
17) Confidence 0.42 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.20 Pain Relevance 0
A human EGFR phosphorylation antibody array (RayBioTech, USA) was used to simultaneously detect phosphorylation of 17 different sites for Human EGFR in cell lysates.
Negative_regulation (detect) of Phosphorylation (phosphorylation) of EGFR
18) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2777152 Disease Relevance 0.42 Pain Relevance 0.04
A human EGFR phosphorylation antibody array (RayBioTech, USA) was used to simultaneously detect phosphorylation of 17 different sites for Human EGFR in cell lysates.
Negative_regulation (detect) of Phosphorylation (phosphorylation) of EGFR
19) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2777152 Disease Relevance 0.43 Pain Relevance 0.04
In a preclinical model, lapatinib was shown to inhibit the formation of brain metastases in a breast cancer xenograft mode.32 In this murine model, lapatinib inhibited phosphorylation of EGFR, HER2 and associated downstream proteins.
Negative_regulation (inhibited) of Phosphorylation (phosphorylation) of EGFR in brain associated with breast cancer and metastasis
20) Confidence 0.37 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 1.35 Pain Relevance 0.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox